CIL 34546-NSR-REP-01

Clinical Trial

NCT01461213 Completed

Gene therapy study on choroideremia : to assess the safety and tolerability of the AAV.REP1 vector, administered at two different doses to the retina in patients with a diagnosis of choroideremia.

Phase 1/2

Interventional

Disease

Disease type

Choroideremia

Orphan drug recognition

Yes

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

01/06/2017

Closing date

31/08/2018

Inclusion criteria :

Exclusion criteria :

Funding

industry

Members involved

Main investigators

Pr Isabelle MEUNIER

Representative

France

Retinal Rare Eye Diseases (WG1)

ERN EYE member investigating site

HCP : Principal investigators

Reference Center Rare Diseases ‘Genetic Sensory Diseases’, MAOLYA, Montpellier, France

Adress

Hôpital Gui de ChauliacService Ophtalmologie80, avenue Augustin Fliche 1er étage, bureau 1414

34 295 Montpellier Cedex 5

France

Contact

04 67 33 02 78

Website

See full page

Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Accessibility

CIL 34546-NSR-REP-01

In this page

Clinical Trial

Disease

Inclusion / Exclusion

Funding

Members involved

Main investigators

Pr Isabelle MEUNIER

ERN EYE member investigating site

HCP : Principal investigators

Reference Center Rare Diseases ‘Genetic Sensory Diseases’, MAOLYA, Montpellier, France

Adress

Contact

CONTACT US